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Aim To assess the effects of single nucleotide polymor-
phisms (SNPs) on blood pressure control in patients with 
obstructive sleep apnea (OSA).
Methods This prospective observational cohort study, 
conducted between 2004 and 2014, examined the asso-
ciations of SNPs of JAG1, GUCY1A3-GUCY1B3, SH2B3, and 
NPR3-C5orf23 genes with systolic and diastolic blood pres-
sure (SBP, DBP) in 1179 adults evaluated for OSA with over-
night polysomnography. Genotyping was performed by 
unlabeled probe melting analysis.
Results The patients were predominantly male (69.6%, 
mean age 52 ± 11 years, apnea-hypopnea index 34 ± 31 
episodes/h). Only JAG1 genotype was associated with SBP 
and DBP: compared with AA homozygotes, G allele carri-
ers (pooled GG and AG genotype) had significantly high-
er morning SBP (132 ± 19 vs 129 ± 18 mm Hg; P = 0.009) 
and morning and evening DBP (85 ± 11 vs 83 ± 10 mm Hg, 
P = 0.004; 86 ± 10 vs 84 ± 10 mm Hg, P = 0.012, respective-
ly); the differences remained significant after the correc-
tion for multiple SNPs testing. In multivariate analyses, oxy-
gen desaturation index and JAG1 genotype independently 
predicted morning SBP (P = 0.001, P = 0.003, respectively) 
and DBP (P < 0.001, P = 0.005, respectively), and evening 
SBP (P = 0.019, P = 0.048, respectively) and DBP (P = 0.018, 
P = 0.018, respectively).
Conclusion This is the first replication study of the SNPs 
recently linked to arterial hypertension in general popu-
lation by genome-wide association studies. Our findings 
suggest that JAG1 genotype is related to blood pressure 
control in OSA: G allele was associated with higher morn-
ing and evening SBP and DBP.
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Blood pressure is a multifactorial trait. International guide-
lines for the management of arterial hypertension recog-
nize obstructive sleep apnea (OSA) as the most prevalent 
cause of secondary hypertension (1) and the most impor-
tant factor in drug-resistant hypertension (2). Increases in 
OSA severity are directly linked to increases in systolic and 
diastolic blood pressure (SBP, DBP) and to the odds for the 
development of arterial hypertension (3).
Another factor that profoundly affects blood pressure 
control is heredity. Approximate heritability of blood pres-
sure ranges between 30%-50% (4). The material basis for 
this heritability is coded in two types of genetic variants: a) 
major-effect genetic variants that are responsible for rare 
familial hypertension syndromes, contributing to blood 
pressure increases at the level of several millimeters of 
mercury (mmHg), b) small-effect genetic variants that in-
dependently influence blood pressure at the level of up 
to 1 mm Hg for SBP and of up to 0.5 mm Hg for DBP (4,5). 
Small-effect genetic variants include repetition muta-
tions, inversions, and, most importantly, single nucleotide 
polymorphisms (SNPs), which may occur throughout the 
genome in coding, non-coding, and regulator parts of 
genes. Several genome-wide association studies (GWASs) 
revealed signals in particular genetic loci linked to blood 
pressure control in general population and identified 
over 100 SNPs associated with either blood pressure in-
crease or arterial hypertension (6). Nevertheless, the iden-
tified loci linked to blood pressure were seldom localized 
inside or close to regions with known function in blood 
pressure control. In contrast, most of the SNPs identified 
by GWASs were located next to genes with pleiotropic ef-
fects, such as prenatal cardiovascular development, inter- 
and intracellular signaling, hematopoiesis, or metabolism 
of natriuretic peptides (4). Moreover, several of the newly 
identified SNPs linked to blood pressure control were in 
previous studies associated with the increased risk of cor-
onary artery disease (7).
Although GWASs recognized the effects of certain SNPs 
on blood pressure regulation in the general popula-
tion (5-7), there is a paucity of data about the potential 
effects of these SNPs in patients with pre-existing medi-
cal conditions known to modify blood pressure control. 
The present study aimed to evaluate the associations be-
tween blood pressure and selected gene polymorphisms 
with GWAS-recognized effects on blood pressure con-
trol (rs3184504 of the SH2B3 gene, rs1327235 of the 
JAG1 gene, rs13139571 of the GUCY1A3-1B3 gene, and 
rs1173771 of the NPR3c5orf23 gene) in individuals 
referred to a sleep laboratory for OSA evaluation. The se-
lection of four distinct SNPs was guided by several pre-
vious studies that identified the relationships between 
these polymorphisms and blood pressure, arterial hyper-
tension, and coronary artery disease in general popula-
tion as summarized by Waken et al (6).
PaTIenTs and meTHods
Patients
In this prospective observational cohort study, 1179 indi-
viduals referred to the sleep unit at a tertiary referral uni-
versity hospital (Department of Respiratory Medicine, L. 
Pasteur University Hospital, Košice, Slovakia) for a diagnos-
tic sleep study were recruited consecutively between 2004 
and 2014. They were all clinically stable adults (age over 18 
years) with or without OSA. Exclusion criteria were respira-
tory failure, arterial hypertension secondary to a disease dif-
ferent from OSA, and any cardiovascular instability includ-
ing accelerated hypertension. The study was approved by 
the L. Pasteur University Hospital Ethics Committee, and all 
patients gave written informed consent.
sleep assessment
All patients underwent overnight polysomnography (Alice 
4 and Alice 5; Respironics Inc., Murrysville, PA, USA), which 
consisted of electroencephalography (EEG), electroocu-
lography, electromyography, thoracic and abdominal im-
pedance belts, thermistor flowmeter for nasal and oral air-
flow, microphone for snoring, and pulse oximetry. Records 
were scored manually following the criteria of the Ameri-
can Academy for Sleep Medicine (AASM) 2007 guidelines 
and 2012 update (8).
Apnea was defined as a reduction of airflow of ≥90% from 
the baseline with duration ≥10 s; hypopnea was defined 
as a reduction in airflow of ≥50% of baseline for ≥10 s, fol-
lowed by a decrease in oxygen saturation for ≥3%, arousal, 
or both. Alternatively, hypopnea was identified if reduc-
tion of airflow ≥30% from the baseline was present and 
accompanied with a decrease in saturation ≥4%. Apnea/
hypopnea index (AHI) was defined as the total number of 
apneic and hypopneic events per hour of sleep. Oxygen 
desaturation index (ODI) was calculated as the number of 
episodes of reductions in oxygen saturation of ≥3% per 
hour of sleep, and arousal index was used as a marker of 
sleep fragmentation characterized as the number of arous-
als on EEG recording per hour of sleep.
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Patients with AHI less than five episodes per hour had no OSA. 
In patients diagnosed with OSA, its severity was classified 
based on AASM guidelines, with AHI≥5 and <15 episodes/h 
labeled as mild OSA, AHI≥15 and <30 episodes/h as moder-
ate OSA, and AHI≥30 episodes/h as severe OSA (9).
Blood pressure measurements
Blood pressure was measured in a sitting position by us-
ing a certified manometric device in the evening, immedi-
ately before the montage of polysomnographic leads after 
at least of 10 minutes of no physical effort (10), and in the 
morning after awakening before the removal of the leads. 
Systolic and diastolic blood pressure were measured three 
times by a trained nurse, and the mean value of the last 
two measurements was recorded. Manual sphygmoma-
nometer (Welch Allyn type Gold Seriers DS66 Trigger An-
eroids, Chicago, IL, USA) with annually certified accuracy of 
±2.5% was used for all blood pressure measurements.
Genotyping
Peripheral blood samples for leukocyte DNA extraction 
were collected by a trained nurse by venipuncture of the 
cubital vein in the morning after diagnostic polysomnog-
raphy. DNA was extracted with the QIAamp DNA Blood 
Mini QIAcube Kit according to the manufacturer’s instruc-
tions on the QIAcube – robotic workstation for automat-
ed purification of DNA, RNA, or proteins (QIAGEN, Hilden, 
Germany). Four variants of interest were analyzed by high-
resolution melting analysis (HRMA) after real-time poly-
merase chain reaction in the presence of LCGreen Plus dye 
(BioFire Defense, Salt Lake City, UT, USA) on Eco Real-Time 
PCR System (Illumina Inc., San Diego, CA, USA). Specifically, 
SH2B3 rs3184504, JAG1 rs1327235, GUCY1A3 rs13139571, 
NPR3 rs1173771 polymorphisms were identified by HRMA 
in the presence of unlabeled probe. The oligonucleotide 
sequences used for the analyses (Sigma-Aldrich, Haverhill, 
UK) are shown in Table 1. Genotypes were identified using 
EcoTM Software 4.1. Genotyping success rate for all exam-
ined variants was 100%, and duplicate genotyping concor-
dance was 100% (5 samples for each genotype).
statistical analysis
Normality of the distribution was assessed by Kolmogorov-
Smirnov test. The data are presented as mean ± standard de-
viation (SD). Differences between groups were analyzed us-
ing one way ANOVA for parametric variables and ANOVA on 
ranks for nonparametric variables. Holm-Sidak test was used 
for post hoc pair-wise comparisons between groups with 
different OSA severity. Differences in proportions between 
groups were analyzed with χ2 test. A two-tailed P-value of 
<0.05 was considered significant for comparisons between 
groups with different OSA severity. The alleles of the select-
ed SNPs that confer an increase in blood pressure were ref-
erenced according to the genome database in the project 
Ensebml GRCh38 (11). For comparisons between the respec-
tive genetic variants for each genotyped polymorphism, the 
cohort was divided into two groups (a dominant model): the 
first group comprised the individuals with one or more copy 
of the risky allele (ie, conferring an increase in blood pressure) 
and the second group comprised the homozygotes for the 
non-risky allele. Consequently, after applying the Bonferroni 
TaBLe 1. oligonucleotides sequences (sigma-aldrich, Haverhill, UK) used in genotyping of variants of interest
Gene (risky/non-risky allele) oligonucleotide sequence 5'→3’
SH2B3 (T/C) forward-limit AGCAGCTTGCTCCAGCATC
reverse-excess TGTAAAGGTTGTCAGGCATCTC
probe GAGGTCCGGCGGTGCACAC-Phos
JAG1 (G/A) forward-excess CTAACCAACACTTGGCATAGACTC
reverse-limit CATCATGAAAATGTGAATTCAAACTCCAG
probe AAATCCCACGTATGCCACCAGAACAA-Phos
GUCY1A3 (C/A) forward-limit ATTCCTTGTTTCCAAGTCCGGCTTC
reverse-excess GTGAGTATAGACAACTTCTTTCAGTTTTGC
probe CTACAATTTTCAATTTCTGCTCTG-Phos
NPR3 (G/A) forward-limit CTGAATATTTCTGACCTTGCAGCTC
reverse-excess TGGGGACACAGCCAACCAT
probe CTGCTGGTGCTTTGTGAATAAGTTGGTAT-Phos
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correction for 4 tested SNPs, a P-value of <0.0125 was con-
sidered significant (α = 0.05/4 = 0.0125). Graphic outputs of 
the blood pressure comparisons between genotype groups 
were created with SigmaPlot version 8 (SPSS, Chicago, IL, 
USA) and Microsoft Powerpoint (Redmond, WA, USA). Linear 
relationships between blood pressure and indices of OSA se-
verity were analyzed by calculating the Pearson correlation 
coefficient. In multivariate analyses, multiple linear regres-
sion models were used with blood pressure as a dependent 
variable, and age, sex, body mass index (BMI), antihyperten-
sive use, ODI, and genotype as independent variables. As-
sociations in the linear regression models are presented as 
nominally significant (P < 0.05). All analyses were carried out 
using SPSS, version 14 (IBM, Chicago, IL, USA).
Hardy-Weinberg equilibrium for each genotype was tested 
using an online calculator (http://www.oege.org/software/
hwe-mr-calc.shtml). The genotypes were considered to be 
distributed as expected under Hardy-Weinberg equilibri-
um if the calculated χ2 was <3.84 (ie, P value ≥0.05) (12).
ResULTs
Cohort characteristics
The study involved 1179 participants (821 or 69.6% men) 
with mean age 52.0 ± 11.4 years (18 to 81 years; median [in-
terquartile range] of 54.0 [45.0-60.0] years) and mean AHI 
34.4 ± 30.9 episodes/h (0.1 to 157.8 episodes/h; median [in-
TaBLe 2. demographic characteristics and polysomnographic findings in the study participants*†
entire cohort no osa mild osa moderate osa severe osa P
Participants (n) 1179 202 250 186 541
sex
male 821 (70) 101 (50) 168 (67) 125 (67) 427 (79) <0.001
female 358 (30) 101 (50)  82 (33)  61 (33) 114 (21)
age (years)  52.0 ± 11.4  47.2 ± 11.9  51.4 ± 11.8  52.9 ± 11.3  53.9 ± 10.4 <0.001
BmI (kg/m2)  32.5 ± 6.6  28.5 ± 4.8  30.2 ± 5.9  32.0 ± 5.9  35.2 ± 6.5 <0.001
Current smoker 388 (33)  67 (33)  76 (30)  53 (28) 192 (35) 0.262
arterial hypertension 732 (62)  92 (46) 120 (48) 122 (66) 398 (74) <0.001
Type 2 diabetes 161 (14)   7 (3)  22 (9)  29 (16) 103 (19) <0.001
Cad 198 (17)  21 (10)  30 (12)  35 (19) 112 (21) <0.001
mI  56 (5)   5 (2)   5 (2)  11 (6)  35 (6) 0.014
stroke  52 (4)   4 (2)   6 (2)   9 (5)  33 (6) 0.032
antihypertensives 680 (58)  81 (41) 116 (47) 115 (63) 368 (68) <0.001
alpha blockers  97 (8)  8 (4)  15 (6)  17 (9)  57 (11) 0.015
Beta blockers 333 (29)  40 (20)  49 (20)  55 (30) 189 (35) <0.001
Calcium channel blockers 291 (25)  33 (17)  47 (19)  47 (26) 164 (31) <0.001
diuretics 248 (21)  19 (10)  33 (13)  37 (20) 159 (30) <0.001
aCeI 315 (27)  30 (15)  52 (21)  55 (30) 178 (33) <0.001
sartans 174 (15)  19 (10)  27 (11)  22 (12) 106 (20) <0.001
nRem (min) 357.3 ± 64.3 344.3 ± 59.0 350.5 ± 59.3 347.4 ± 61.2 368.6 ± 67.7 <0.001
s1 nRem (min)  58.6 ± 49.6  49.2 ± 45.5  51.1 ± 37.2  51.9 ± 39.9  67.9 ± 57.1 <0.001
s2 nRem (min) 249.1 ± 77.8 237.9 ± 67.5 239.0 ± 65.5 233.7 ± 66.8 263.3 ± 87.4 <0.001
sWs (min)  49.5 ± 35.1  57.2 ± 35.1  60.5 ± 35.2  61.7 ± 34.7  37.4 ± 31.2 <0.001
Rem (min)  60.7 ± 34.8  64.3 ± 36.0  69.0 ± 31.4  66.9 ± 34.7  53.4 ± 34.6 <0.001
aHI (episodes/h)  34.5 ± 30.9   2.4 ± 1.5   9.6 ± 2.9  21.3 ± 4.0  62.6 ± 23.4 <0.001
odI (episodes/h)  29.5 ± 30.0   3.2 ± 8.3   7.4 ± 7.0  16.7 ± 9.7  53.8 ± 27.3 <0.001
Arousal index (episodes/h) 37.3 ± 25.2  18.0 ± 13.5  22.6 ± 12.2  28.0 ± 12.7  54.5 ± 25.0 <0.001
SpO2<90% (min)  58.1 ± 101.6  19.0 ± 81.0  15.0 ± 58.8  27.0 ± 73.1 103.1 ± 113.3 <0.001
Lowest SpO2 (%)  77.4 ± 15.8  89.4 ± 5.8  86.1 ± 5.8  81.3 ± 9.5  67.7 ± 17.1 <0.001
*osa – obstructive sleep apnea; BmI – body mass index; Cad – coronary artery disease; mI – myocardial infarction; aCeI – inhibitors of angiotensin-
converting enzyme; nRem – non-rapid eye movement sleep; s1 nRem – stage 1 nRem sleep; s2 nRem – stage 2 nRem sleep; sWs – slow wave sleep; 
Rem – rapid eye movement sleep; aHI – apnea/hypopnea index; odI – oxygen desaturation index; spo2 – arterial oxygen saturation measured by 
pulse oximetry.
†data are presented as number (n) and percentage (%) or mean ± standard deviation, unless otherwise stated. P-values were calculated using one 
way anoVa and χ2 test as appropriate.
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terquartile range] of 24.0 [8.1-55.6] episodes/h]. A total of 
202 patients had no OSA, 250 had mild OSA, 186 had mod-
erate OSA, and 541 had severe OSA. Basic demographic 
data are shown in Table 2. The severity of OSA was signifi-
cantly associated with male sex, older age, BMI, increasing 
prevalence of arterial hypertension as reported in personal 
history, type 2 diabetes, cardiovascular and cerebrovascu-
lar morbidity, and the use of antihypertensive drugs. All 
genotypes were evenly distributed among all OSA severity 
categories (P value >0.05 for each respective genotype).
association of osa with blood pressure
Morning and evening SBP and DBP increased with in-
creasing OSA severity, with the highest values in patients 
with severe OSA (Table 3). Morning SBP and DBP were 
positively correlated with AHI (R = 0.212 and R = 0.210, re-
spectively), arousal index (R = 0.200 and R = 0.191, respec-
tively), desaturation index (R = 0.239 and R = 0.216, respec-
TaBLe 3. Blood pressure values in participants grouped by severity of obstructive sleep apnea (osa)*
no osa mild osa moderate osa severe osa P
Participants (n) 202 250 186 541
Morning systolic blood pressure (mmHg) 126.7 ± 19.1 126.4 ± 16.7 130.2 ± 17.3 135.5 ± 18.5†‡§ <0.001
Morning diastolic blood pressure (mmHg)  81.7 ± 11.5  82.7 ± 10.3  83.6 ± 10.0  87.1 ± 10.9†‡§ <0.001
Evening systolic blood pressure (mmHg) 128.7 ± 16.3 131.8 ± 16.3 132.5 ± 18.1 136.5 ± 18.3†‡ <0.001
Evening diastolic blood pressure (mmHg)  83.3 ± 9.2  84.9 ± 8.8  85.0 ± 10.3  86.6 ± 10.2†  0.003
*data are presented as mean ± standard deviation, unless otherwise stated. P- values were calculated using one way anoVa.
†P-value <0.05 vs no osa.
‡P-value <0.05 vs mild osa.
§P-value <0.05 vs moderate osa.
TaBLe 4. Basic demographic characteristics in participants 
grouped by JAG1 genotype*†
JAG1 polymorphism genotype
aa aG+GG P
Participants (n) 360 819
Male sex 252 (70) 569 (69) 0.911
Age (years)  52.5 ± 10.6  51.8 ± 11.7 0.420
BMI (kg/m2) 32.4 ± 6.7  32.5 ± 6.5 0.581
Antihypertensive 
medication users
207 (58) 473 (58) 0.965
AHI (episodes/h)  34.2 ± 31.6  34.6 ± 30.6 0.719
ODI (episodes/h)  29.2 ± 31.2  29.7 ± 29.4 0.424
No OSA  61 (17) 141 (17)
0.358
Mild OSA  82 (23) 168 (21)
Moderate OSA  64 (18) 122 (15)
Severe OSA 153 (42) 388 (47)
*BmI – body mass index; aHI – apnea-hypopnea index; odI – oxygen 
desaturation index; osa – obstructive sleep apnea.
†data are presented as number (n) and percentage (%) or mean ± stan-
dard deviation, unless otherwise stated.
TaBLe 5. Blood pressure across obstructive sleep apnea severity groups in aa homozygotes and G allele carriers of the JAG1 gene 
polymorphism*†
no osa mild osa moderate osa severe osa P
morning sBP
AA 123.4 ± 13.8 123.9 ± 16.5 127.8 ± 17.5 134.7 ± 18.8‡§ <0.001
AG+GG 128.1 ± 20.9 127.6 ± 16.7 131.5 ± 17.1 135.9 ± 18.3‡§ <0.001
morning dBP
AA  79.2 ± 8.9  81.5 ± 9.6  82.1 ± 9.6  86.5 ± 10.8‡§ <0.001
AG+GG  82.7 ± 12.3  83.2 ± 10.6  84.3 ± 10.1  87.4 ± 11.0‡§ <0.001
evening sBP
AA 125.5 ± 12.7 130.3 ± 15.6 132.2 ± 20.2 135.2 ± 17.3‡  0.003
AG+GG 130.1 ± 17.5 132.6 ± 16.7 132.6 ± 16.9 137.0 ± 18.7‡  0.001
evening dBP
AA  82.6 ± 8.7  84.1 ± 8.5  84.5 ± 10.6  85.0 ± 9.9  0.438
AG+GG  83.6 ± 9.4  85.3 ± 8.9  85.3 ± 10.2  87.2 ± 10.3‡  0.010
*osa – obstructive sleep apnea; sBP – systolic blood pressure; dBP – diastolic blood pressure.
†data are presented as mean ± standard deviation in millimeters of mercury (mmHg). P-values were calculated using one way anoVa.
‡P-value <0.05 vs no osa.
§P-value <0.05 vs mild osa.
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tively), and time spent in saturation under 90% (R = 0.182 
and R = 0.158, respectively), with P < 0.001 for all. Evening 
SBP and DBP were positively correlated with AHI (R = 0.171 
and R = 0.129, respectively), arousal index (R = 0.138 and 
R = 0.107, respectively), and desaturation index (R = 0.186 
and R = 0.145, respectively), with P < 0.001 for all, and eve-
ning SBP was correlated with time in desaturation under 
90% (R = 0.094, P = 0.002).
association of selected genotypes with blood pressure
Significant differences in SBP and DBP were observed be-
tween the genotype groups of polymorphism in the JAG1 
gene. Alleles A and G of JAG1 gene polymorphism were 
distributed according to Hardy-Weinberg equilibrium. Sex 
distribution, age, BMI, AHI, ODI, antihypertensive medica-
tion use, and the proportion of patients according to OSA 
severity were similar in the two JAG1 genotype groups 
(Table 4).
JAG1 polymorphism genotypes were associated with 
blood pressure in the entire cohort (Figure 1). After apply-
ing the Bonferroni correction for 4 genotyped SNPs, allele 
G carriers (pooled homozygotes GG and heterozygotes 
AG) had significantly higher morning SBP (132.2 ± 18.6 vs 
129.1 ± 17.9 mm Hg, P = 0.009), morning DBP (85.3 ± 11.2 vs 
FIGURe 1. Comparison of the systolic and diastolic blood pressure between aa homozygotes and G allele carriers of JAG1 gene 
polymorphism; *P-value <0.0125 vs aa homozygotes. White – aa; gray – aG+GG.
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83.3 ± 10.4 mm Hg, P = 0.004), and evening DBP (85.9 ± 9.9 
vs 84.3 ± 9.5 mm Hg, P = 0.012) than allele A homozygotes.
We also examined the association of OSA severity with 
blood pressure in the distinct JAG1 polymorphism geno-
type groups. G allele carriers with severe OSA had signifi-
cantly higher morning and evening SBP and DBP (P < 0.05 
for all) than G allele carriers with no OSA. In addition, AA 
homozygotes with severe OSA had higher morning SBP 
and DBP (P < 0.05 for both), and evening SBP (P < 0.05) 
compared with AA homozygotes with no OSA (Table 5).
To further investigate the association of both intermittent 
hypoxia and JAG1 genotype with blood pressure control, 
we performed multivariate analyses using multiple lin-
ear regression models with each respective blood pres-
sure value as a dependent variable and age, sex, BMI, use 
of antihypertensive medication, ODI, and JAG1 genotype 
as independent variables. Both ODI and JAG1 genotype 
were significant and independent predictors of morning 
and evening SBP and DBP (P < 0.05 for both, Table 6). Intro-
ducing AHI instead of ODI as an index of OSA severity in 
multivariate linear models yielded similar results (data not 
shown). Finally, we also analyzed a potential independent 
association of an interaction term JAG1 genotype*ODI 
with blood pressure by adding the interaction term to the 
previous models. Nevertheless, the JAG1 genotype*ODI in-
teraction term was not a significant predictor of either SBP 
or DBP in any of the models.
No significant associations between the further three test-
ed SNPs (SH2B3, GUCY1A3-GUCY1B3, and NPR3c5orf23) and 
blood pressure were observed (Table 7).
dIsCUssIon
The present genetic association study revealed that among 
patients with suspected OSA, carriers of the risky G allele 
of the rs1327235 polymorphism of JAG1 gene had signifi-
cantly higher morning SBP and DBP, and evening DBP than 
AA homozygotes. The association of JAG1 genotype with 
blood pressure was independent of age, sex, BMI, and use 
of antihypertensive medication. Moreover, our data indi-
cate that OSA severity has deleterious effects on blood 
pressure independently of the effect carried by the JAG1 
genotype. Previously, several GWASs reported links be-
tween JAG1 genotype and increased SBP and DBP, and 
higher odds of hypertension and coronary artery disease 
in the general population (5,13). In individuals of Euro-
pean descent, effect size estimate of coded allele G 
TaBLe 6. multivariate models with systolic and diastolic blood pressure as dependent variables*
systolic blood pressure diastolic blood pressure










Age 0.348 0.050 <0.001 0.191 0.051 <0.001 0.089 0.031 0.004 0.032 0.029 0.277
Sex -0.458 1.122 0.683 -0.757 1.156 0.513 -1.510 0.697 0.031 -1.726 0.664 0.009
Body mass index 0.348 0.098 <0.001 0.238 0.100 0.017 0.152 0.061 0.013 0.072 0.057 0.208
Antihypertensive use 4.671 1.200 <0.001 5.031 1.223 <0.001 1.895 0.746 0.011 1.080 0.702 0.124
Oxygen desaturation index 0.068 0.021 0.001 0.051 0.021 0.019 0.045 0.013 <0.001 0.029 0.012 0.018
JAG1 genotype 3.211 1.085 0.003 2.201 1.113 0.048 1.884 0.674 0.005 1.512 0.639 0.018
*P-value for each variable in the model presented. model for morning systolic blood pressure R2 = 0.16; F = 37.5, P < 0.001; model for evening systolic 
blood pressure R2 = 0.10; F = 19.0, P < 0.001; model for morning diastolic blood pressure R2 = 0.08, F = 17.6, P < 0.001; model for evening diastolic blood 
pressure R2 = 0.04, F = 7.1, P < 0.001.
TaBLe 7. associations between single-nucleotide polymorphisms SH2B3, GUCY1A3-GUCY1B3, and NPR3c5orf23 and blood pressure*†
P
single-nucleotide polymorphism Risky/non-risky allele (participant) morning sBP morning dBP evening sBP evening dBP
SH2B3 CC (268)/CT+TT (911) 0.414 0.734 0.801 0.207
GUCY1A-GUCY1B AA (93)/AC+CC (1086) 0.322 0.172 0.679 0.292
NPR3C5orf23 AA (199)/AG+GG (980) 0.362 0.791 0.088 0.076
*sBP – systolic blood pressure; dBP – diastolic blood pressure.
†P-value for comparisons of the respective blood pressures between the two genotype groups for each single-nucleotide polymorphism is pre-
sented.
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was 0.340 mm Hg for SBP, 0.302 mm Hg for DBP, and 0.034 
in odds for hypertension (5). Furthermore, Wain et al (13) 
reported a relationship between rs1327235 and the mean 
arterial pressure and pulse pressure in healthy individuals. 
Our study is the first to replicate the GWAS-documented 
association between the rs1327235 polymorphism of the 
JAG1 gene and blood pressure control, and to suggest that 
the rs1327235 polymorphism of JAG1 gene may be in-
volved in blood pressure regulation in patients with OSA.
The prevalence of hypertension in OSA ranges from 30 to 
85%, while the prevalence of OSA among hypertensive 
patients is 40% (14). The association between OSA and hy-
pertension is independent of confounders such as obe-
sity, smoking, or alcohol intake (15). Increasing severity of 
sleep apnea is proportional to the increase in blood pres-
sure and incidence of hypertension (15). Moreover, OSA 
has been identified as a prevalent underlying condition in 
drug-resistant hypertension (2,16). An important mediator 
for systemic hypertension in patients with OSA is chronic 
intermittent hypoxia (15). This type of hypoxia contributes 
to additional factors related to increases in blood pres-
sure: sympathetic activation, blunted baroreflex sensitivity 
(17), increased chemosensory activity of the carotid body 
(18), and endothelial dysfunction (19). In the studied co-
hort, the differences in blood pressures between the JAG1 
genotype groups were 2.0-4.5 mm Hg for SBP and 0.9-3.5 
mm Hg for DPB across different OSA severity groups. In-
terestingly, in a GWAS, the mean estimated effect size of 
singular polymorphism was 0.5 mm Hg for DBP and 1.0 
mm Hg for SBP (5). Therefore, the differences observed in 
our study exceeded the average of the expected effect 
size for a singular polymorphism. On the other hand, dif-
ferences in blood pressures attributed to a singular gene 
polymorphism in our and other studies (5) are lower than 
the reported effect size of mutations in familial hyperten-
sive syndromes, which was 10 mm Hg for SBP (4). In the 
present study, the differences in SBP and DBP between pa-
tients with severe OSA and those without OSA were up to 
9 and 6 mm Hg, respectively. These results are comparable 
to those observed by Peppard et al (15) in their landmark 
prospective study.
Several genetic association studies have reported links 
between genetic background and arterial hypertension 
in OSA. Lavie et al (20) reported that OSA patients with 
haptoglobin phenotype 2-2 had increased susceptibility 
to hypertension compared with OSA patients with hap-
toglobin phenotype 2-1. Riha et al (21) demonstrated 
an association between tumor necrosis factor-alpha 
polymorphism and OSA severity; nevertheless, no relation-
ship between tumor necrosis factor-alpha polymorphism 
and hypertension was observed. Considering the crucial 
role of sympathetic nervous system activation in the OSA-
related arterial hypertension, genetic background of β
2-
adrenergic receptor was also investigated: heterozygosity 
for the β2-adrenergic receptor was associated with a lower 
rate of post-myocardial infarction survival in patients with 
OSA and a high cardiovascular risk profile. However, func-
tionally relevant polymorphisms of β2-adrenergic receptor 
did not modify blood pressure induced by OSA (22). In an-
other study, β1-adrenergic receptor gene Arg389Arg gen-
otype was associated with an increased prevalence of hy-
pertension in individuals with mild OSA (23). The results on 
the role of angiotensin-converting enzyme gene insertion/
deletion (I/D) polymorphism in blood pressure in patients 
with OSA yielded conflicting results. While in one study, the 
D allele of the I/D polymorphism was linked with central 
obesity but not with OSA or hypertension (24), in another 
it was associated with hypertension only (25). Interesting-
ly, Patel et al (26) observed a protective effect of D allele 
against hypertension in severe OSA, and Boström (27) re-
ported a significant interaction between OSA and I/D poly-
morphism and the prevalence of hypertension in OSA.
Our study was the first to analyze, in patients with OSA, 
the potential role of polymorphisms originally identified 
in GWASs as being significant in blood pressure regula-
tion in general population. Therefore, our results on the 
associations between the JAG1 gene polymorphism and 
morning and evening SBP and DBP in patients with OSA 
confirm and extend the previous results on the role of 
JAG1 genotype in blood pressure control. JAG1 gene is 
localized on chromosome 20. It codes jagged 1 protein 
that serves as a ligand for multiple Notch receptors. Notch 
signaling is an evolutionary conserved short-range inter-
cellular pathway with a role in many essential processes, 
such as cell fate determination during embryonic devel-
opment, vascular morphogenesis, angiogenesis, pheno-
typic switching, and vascular remodeling after injury (28). 
Recently, JAG1 has been implicated in the pathogenesis 
of pulmonary arterial hypertension by aggravating pul-
monary vascular remodeling both in animal studies (29) 
and in patients with tetralogy of Fallot and pulmonary 
stenosis (30). Mechanisms underlying the association be-
tween JAG1 genotype and systemic hypertension might 
parallel those observed in pulmonary hypertension, but 
experimental data for this hypothesis are lacking. Of note, 
a human clinical condition with autosomal dominant her-
itability, termed Alagille syndrome, involves both major 
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frameshift mutations of JAG1 gene and systemic arterial 
hypertension (31). Nevertheless, direct pathophysiologi-
cal links between JAG1 genotype and blood pressure con-
trol remain to be elucidated.
The main strength of our study is a distinct cohort of pa-
tients who underwent full attended polysomnography, 
which is a fundamental method in diagnosing sleep dis-
ordered breathing. Nevertheless, several limitations to the 
current study need to be also acknowledged. First, only 
a minority of the genetic variants significantly associated 
with SBP, DBP, and hypertension in GWAS was near a gene 
with a recognized role in blood pressure control (4). More-
over, the effect size of each individual variant is very small, 
and even collectively, the 29 variants explain only 1%-2% 
of SBP and DBP variance (5). This may clarify the lack of as-
sociations between blood pressure and three of the four 
SNPs tested in the present investigation; further studies in 
much larger cohorts are needed to analyze such potential 
associations in more detail. Second, although our results 
suggest a role for the JAG1 gene in blood pressure con-
trol in patients with OSA, investigation of the underlying 
mechanisms of the observed association was beyond the 
scope of the present study. Therefore, the present results 
should be considered hypothesis-generating, and further 
studies are needed to analyze the relationships between 
the JAG1 gene polymorphism and blood pressure control 
in OSA in more detail.
In conclusion, the present study suggests that the risky G 
allele in the JAG1 genotype is associated with higher morn-
ing and evening SBP and DBP in patients referred to sleep 
laboratory for the evaluation of suspected OSA. Large-
scale genetic studies are needed to elucidate the impact 
of susceptibility polymorphisms that contribute to hyper-
tension in such patients.
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